642 related articles for article (PubMed ID: 24445558)
1. Vitamin D as an early predictor of multiple sclerosis activity and progression.
Ascherio A; Munger KL; White R; Köchert K; Simon KC; Polman CH; Freedman MS; Hartung HP; Miller DH; Montalbán X; Edan G; Barkhof F; Pleimes D; Radü EW; Sandbrink R; Kappos L; Pohl C
JAMA Neurol; 2014 Mar; 71(3):306-14. PubMed ID: 24445558
[TBL] [Abstract][Full Text] [Related]
2. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
[TBL] [Abstract][Full Text] [Related]
3. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.
Soilu-Hänninen M; Aivo J; Lindström BM; Elovaara I; Sumelahti ML; Färkkilä M; Tienari P; Atula S; Sarasoja T; Herrala L; Keskinarkaus I; Kruger J; Kallio T; Rocca MA; Filippi M
J Neurol Neurosurg Psychiatry; 2012 May; 83(5):565-71. PubMed ID: 22362918
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M; Munger KL; Martínez-Lapiscina EH; Barro C; Edan G; Freedman MS; Hartung HP; Montalbán X; Foley FW; Penner IK; Hemmer B; Fox EJ; Schippling S; Wicklein EM; Kappos L; Kuhle J; Ascherio A;
Neurology; 2020 May; 94(18):e1950-e1960. PubMed ID: 32300060
[TBL] [Abstract][Full Text] [Related]
5. The association of serum 25-hydroxyvitamin D levels with multiple sclerosis severity and progression in a case-control study from China.
Zhang Y; Liu G; Han X; Dong H; Geng J
J Neuroimmunol; 2016 Aug; 297():127-31. PubMed ID: 27397085
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Zivadinov R; Qu J; Cookfair D; Duan X; Bang E; Bergsland N; Hussein S; Cherneva M; Willis L; Heininen-Brown M; Ramanathan M
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):189-95. PubMed ID: 21047880
[TBL] [Abstract][Full Text] [Related]
7. Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode.
Plavina T; Singh CM; Sangurdekar D; de Moor C; Engle B; Gafson A; Goyal J; Fisher E; Szak S; Kinkel RP; Sandrock AW; Su R; Kieseier BC; Rudick RA
JAMA Netw Open; 2020 Nov; 3(11):e2016278. PubMed ID: 33151313
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.
Muris AH; Smolders J; Rolf L; Klinkenberg LJ; van der Linden N; Meex S; Damoiseaux J; Hupperts R
PLoS One; 2016; 11(6):e0156122. PubMed ID: 27276080
[TBL] [Abstract][Full Text] [Related]
9. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial.
O'Connell K; Kelly S; Kinsella K; Jordan S; Kenny O; Murphy D; Heffernan E; O'Laoide R; O'Shea D; McKenna C; Cassidy L; Fletcher J; Walsh C; Brady J; McGuigan C; Tubridy N; Hutchinson M
Trials; 2013 Aug; 14():272. PubMed ID: 23981773
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes.
Martinelli V; Dalla Costa G; Colombo B; Dalla Libera D; Rubinacci A; Filippi M; Furlan R; Comi G
Mult Scler; 2014 Feb; 20(2):147-55. PubMed ID: 23836877
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection.
Mowry EM; Pelletier D; Gao Z; Howell MD; Zamvil SS; Waubant E
Eur J Neurol; 2016 Feb; 23(2):327-32. PubMed ID: 26518224
[TBL] [Abstract][Full Text] [Related]
12. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
[TBL] [Abstract][Full Text] [Related]
13. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis.
Soilu-Hänninen M; Laaksonen M; Laitinen I; Erälinna JP; Lilius EM; Mononen I
J Neurol Neurosurg Psychiatry; 2008 Feb; 79(2):152-7. PubMed ID: 17578859
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
[TBL] [Abstract][Full Text] [Related]
17. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Munger KL; Fitzgerald KC; Freedman MS; Hartung HP; Miller DH; Montalbán X; Edan G; Barkhof F; Suarez G; Radue EW; Sandbrink R; Kappos L; Pohl C; Ascherio A
Neurology; 2015 Nov; 85(19):1694-701. PubMed ID: 26453645
[TBL] [Abstract][Full Text] [Related]
18. Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
Weinstock-Guttman B; Zivadinov R; Horakova D; Havrdova E; Qu J; Shyh G; Lakota E; O'Connor K; Badgett D; Tamaño-Blanco M; Tyblova M; Hussein S; Bergsland N; Willis L; Krasensky J; Vaneckova M; Seidl Z; Ramanathan M
J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1186-91. PubMed ID: 23595944
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D and axonal injury in multiple sclerosis.
Sandberg L; Biström M; Salzer J; Vågberg M; Svenningsson A; Sundström P
Mult Scler; 2016 Jul; 22(8):1027-31. PubMed ID: 26462862
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 May; 18(1):68. PubMed ID: 29751787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
